Omecamtiv mecarbil for heart failure: Unpacking the latest systematic review and meta-analysis

In February 2023, a systematic review and meta-analysis of six randomized controlled trials (RCTs) with a total of 9,596 patients assessed the effectiveness and safety of omecamtiv mecarbil (OM) versus placebo in patients with heart failure with reduced left ventricular ejection fraction (HFrEF). HFrEF is a significant health problem associated with high morbidity and mortality worldwide. OM is a novel drug that targets cardiac myosin, a cytoskeletal motor protein responsible for converting chemical energy to mechanical force.

Institutions

Publication Details

Journal
International Journal of Cardiology and Cardiovascular Diseases
Published
2024-12-31
DOI
https://doi.org/10.46439/cardiology.4.028
Primary Topic
Cardiovascular Function and Risk Factors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Omecamtiv mecarbil for heart failure: Unpacking the latest systematic review and meta-analysis

International Journal of Cardiology and Cardiovascular Diseases
Cardiovascular Function and Risk Factors
article

Omecamtiv mecarbil for heart failure: Unpacking the latest systematic review and meta-analysis

article en

Abstract

In February 2023, a systematic review and meta-analysis of six randomized controlled trials (RCTs) with a total of 9,596 patients assessed the effectiveness and safety of omecamtiv mecarbil (OM) versus placebo in patients with heart failure with reduced left ventricular ejection fraction (HFrEF). HFrEF is a significant health problem associated with high morbidity and mortality worldwide. OM is a novel drug that targets cardiac myosin, a cytoskeletal motor protein responsible for converting chemical energy to mechanical force.

International Journal of Cardiology and Cardiovascular DiseasesVol. 4(1)
University of Arizona (US)
Openalex Percentile: Top 54%
Cardiovascular Function and Risk Factors
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Omecamtiv mecarbil for heart failure: Unpacking the latest systematic review and meta-analysis · International Journal of Cardiology and Cardiovascular Diseases (2024) | TGRS Research Map | TGRS